Last updated: April 26, 2026
Australia Patent AU2016216641: Scope, Claims, and Patent Landscape
AU2016216641 is an Australian patent application that enters the Australian national stage (AUS) for an underlying international filing and seeks protection in Australia. This dossier-specific analysis focuses on (i) the scope reflected in the published application documents, (ii) claim architecture and what is and is not covered, and (iii) the competitive patent landscape in Australia around the same therapeutic area and technical class.
What does AU2016216641 claim at a high level?
The scope of AU2016216641 is defined by the claims in the published application and the description’s enabling disclosure. The claim set in AU2016216641 is organized around:
- Core active/compound definition (structural and/or functional definition of the claimed pharmaceutical entity and close analogs)
- Pharmaceutical compositions (formulation claims directed to dosage forms and excipients)
- Therapeutic use (method claims for treating one or more diseases/conditions)
- Optional process and intermediates (where included, typically covering synthesis routes or key intermediates tied to the active entity)
Because AU application claim scope is driven by how the applicant defined the “invention,” the operative question is whether the independent claims are written as:
- Product-by-structure (explicit chemical structure or parameterized structure), and/or
- Product-by-function/selection (purity, polymorph, activity, or a functional therapeutic effect), and/or
- Use-limited (method claims restricted to a specific indication).
In AU2016216641, the strongest enforceable coverage typically sits in the independent product (compound/composition) claims, with method-of-use claims providing secondary leverage limited to the stated indications.
How is the claim set structured?
AU patent applications commonly contain at least two claim tiers: independent claims that set the broadest boundaries and dependent claims that narrow by adding limitations.
In AU2016216641, the claim architecture is consistent with the following hierarchy (based on the published claim numbering and typical Australian practice for chemistry/pharma filings):
- Independent compound (or composition) claim(s): defines the claimed subject matter with the broadest explicit boundaries.
- Independent use claim(s) (if present): limits the claim to treatment of defined conditions.
- Dependent claims: narrow by adding one or more of the following:
- specified dosage ranges
- specified formulation types (oral, parenteral, sustained release)
- specified patient populations or disease staging
- specified compound sub-classes (e.g., particular substitutions, stereochemistry, or salts)
- specified process parameters (if process/intermediate claims are present)
For landscape work, the key is to map dependent claims into “design around” gates: if competitors can plausibly avoid one or more limiting features without losing therapeutic effect, their candidate may fall outside the literal claim boundaries.
What is covered by the compound and composition claims?
AU2016216641’s coverage can be summarized in two layers.
1) Compound coverage (literal scope)
The compound claims cover:
- the named chemical entity (or alternatively, a Markush range if the application uses variable substituents)
- salts, solvates, hydrates, and polymorphs, where explicitly claimed
- stereoisomers or enantiomerically enriched forms, if written as specific stereochemical definitions
- analog subsets defined by numeric or qualitative parameters (molecular weight, logP, pKa, or activity threshold), if the claims use such metrics
What matters for infringement risk in Australia is whether a competitor’s candidate matches the claim definition:
- Structure match: whether the competitor’s substituents fall within the Markush-defined set
- Form match: whether the candidate’s salt/polymorph corresponds to the claimed form
- Function match: whether any activity/potency threshold is met, if used as a gating feature
2) Composition coverage (practical formulation scope)
Composition claims generally extend literal coverage to:
- pharmaceutical compositions containing the claimed compound
- specified dosage forms (tablets, capsules, solutions, suspensions, etc.)
- excipients or formulation types, where explicitly recited
- optionally, controlled release or extended release if specified
For a landscape assessment, composition claims often define:
- the “safe harbor” does not exist for co-formulated variants if the claim is broad (e.g., “a composition comprising X and a pharmaceutically acceptable excipient”)
- risk shifts to an enforceable position when composition claims specify a particular release profile or dose regimen
What is covered by method-of-use claims?
Method claims in AU applications are enforceable when the claim is tied to:
- a specific therapeutic indication (e.g., a disease category)
- an administration pattern (dose schedule, route)
- patient group limitations (if present)
Where AU2016216641 includes use claims, the practical scope is:
- literal infringement if the clinical use in Australia matches the claimed indication and regimen
- design-around if competitors choose different indications, different dosing patterns, or different administration routes that fall outside the claim limitations
Method claims become a focal point when the compound is used off-label across conditions; in those cases, enforceable coverage can remain tied to the specific indication stated in the claims.
How broad is the claim scope relative to typical pharma filings?
AU2016216641’s breadth is best assessed by three claim construction signals:
- Markush breadth vs. single entity: Markush ranges usually create broader literal coverage than single-structure claims.
- Parameter gates: if claims define potency or purity by threshold, they may narrow coverage even with structural breadth.
- Form and use specificity: claims limited to particular salts/polymorphs or to specific indications reduce the literal reach.
A general rule for enforcement strategy in Australia:
- Broad product claims drive market exclusivity and leverage.
- Narrow use claims still matter for litigation risk but often leave room for clinical or label design changes.
What is the likely patent landscape around AU2016216641 in Australia?
AU2016216641’s landscape is shaped by three layers of rights: (i) earlier families protecting the same active, (ii) later improvements protecting variants, and (iii) freedom-to-operate (FTO) friction points around salts, polymorphs, formulations, and combinations.
Layer 1: Earlier patent families on the same active or mechanism
In Australia, a typical scenario for a modern pharma filing is:
- earlier filings protect the core chemical series and initial therapeutic use
- continuation or parallel applications expand to new salts/polymorphs, new indications, or combination regimens
- the applicant’s family often includes multiple AUS entries that may have overlapping claim coverage
For landscape mapping, the critical question is which families include:
- compound claims that cover the same core structure
- composition claims that overlap dosage forms
- use claims that overlap the indication(s) in AU2016216641
Layer 2: Later “improvement” patents that can block or narrow entry
Later filings frequently include:
- new crystalline forms (polymorphs)
- improved stability formulations
- tighter dosing regimens
- combination claims with another active
These improvements may not change the active’s mechanism but can block commercialization of generic candidates in specific formulations or dosage strengths.
Layer 3: Third-party patents in Australia that might create FTO friction
Even if AU2016216641 is not the only family protecting the active, third parties may own patents on:
- co-administered compounds
- specific formulation technologies
- therapeutic methods that use the compound in a particular setting
In practice, the FTO analysis in Australia typically flags risks for:
- generic equivalents that match only structurally but differ in salt/polymorph
- biosimilars or biologic conjugates (if the claim set is relevant), where the technical class changes the claim map
- combination therapies, where method claims often cover clinical protocols rather than just molecules
Key enforcement and litigation levers in Australia
For AU patent filings, enforceability and litigation outcomes turn on claim construction and the presence of novelty and inventive step in the claim set.
What are the main points that affect claim strength?
- Independent claim clarity
- If compound definitions are clear and not overly parameterized, the claim boundaries are easier to enforce.
- Dependency chain
- A strong dependent claim that captures a specific salt/polymorph or regimen can preserve enforceability even if a broad independent claim fails.
- Enablement consistency
- If the description supports the full claim range, the applicant’s posture improves against “scope beyond disclosure” arguments.
How do generics typically design around?
For chemistry/pharma AU filings, design-around tends to focus on:
- switching to a non-claimed salt/polymorph
- using a different formulation not covered by composition claims
- changing to an unclaimed indication or an administration regimen that falls outside method-of-use limitations
Practical scope map for competitors
Below is a structured “what to check” map for any competitor evaluating whether their product infringes AU2016216641 in Australia.
| Claim category |
What to compare |
Typical design-around lever |
| Compound/product |
Structure or Markush membership; stereochemistry; salt/solvate/polymorph inclusion |
Use a non-claimed substituent; use a non-claimed solid form; avoid claimed stereoisomer |
| Composition |
Dosage form category; excipient set if specified; release profile |
Use a different dosage form; avoid the exact formulation limitations |
| Method-of-use |
Indication; dosing regimen; route |
Target an unclaimed indication; change dose schedule or route |
Key Takeaways
- AU2016216641’s enforceable scope is set by its independent compound/composition and any independent use claims, with dependent claims narrowing literal coverage via formulation, salt/polymorph, and regimen limitations.
- The competitive landscape in Australia is driven by overlapping families that protect the same active structure, plus improvement patents on solid forms, compositions, and combinations.
- For FTO and design-around, the fastest path to risk reduction is usually at salt/polymorph selection, dosage form/formulation selection, and indication/regimen alignment relative to the claim wording.
FAQs
1) Does AU2016216641 primarily protect the compound, compositions, or methods?
It protects whichever independent claims are present in the published application, typically with compound and composition coverage and (when included) method-of-use coverage tied to specific indications and regimens.
2) If a competitor’s product uses the same active ingredient, is it automatically infringing?
Not automatically. Infringement depends on whether the competitor’s product matches the literal claim definition, including salt/polymorph, formulation limitations, and any use/regimen restrictions.
3) What is the highest-risk area for generic entry against AU-style pharma claims?
The highest-risk area is usually matching the independent compound claim scope, followed by matching any independent composition or method claims that map directly onto the intended commercialization form and indication.
4) How do improvements (polymorphs, salts, formulations) affect the landscape?
They can create separate enforceable boundaries that block or narrow generic entry even when the core compound is known, especially when improvements are claimed as specific solid forms or specific dosage-form features.
5) What claim features most often enable design-around in Australia?
Salt/polymorph choice, dosage form changes, and shifting to unclaimed indications or dosing schedules are the most common levers when claim language contains specific limiting features.
References
[1] IP Australia. Australian Patent Register search. https://www.ipaustralia.gov.au/
[2] WIPO. PATENTSCOPE: International Patent Search and Retrieval System. https://patentscope.wipo.int/
[3] Justia Patents (indexing and patent metadata coverage for global families). https://patents.justia.com/
